|
| Press Releases |
|
 |
|
| Wednesday, May 9, 2018 |
|
|
Helsinn Group announces the launch of the IV formulation of AKYNZEO(R) (fosnetupitant/palonosetron) in the United States |
| Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that the intravenous formulation of AKYNZEO(R) (a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) for injection has been launched in the United States by its U.S. subsidiary, Helsinn Therapeutics (U.S.), Inc.. more info >> |
|
| Friday, April 20, 2018 |
|
|
Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO(R) (fosnetupitant/ palonosetron) in the United States |
| Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that the U.S. Food and Drug Administration (FDA) has approved the intravenous formulation of AKYNZEO(R) (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing CINV. more info >> |
|
| Tuesday, April 17, 2018 |
|
|
Taiho Pharmaceutical and Helsinn Group present preclinical data at AACR Annual Meeting for a RET inhibitor under co-development as an attractive compound for anticancer therapy |
| Taiho Pharmaceutical Co., Ltd., a Japanese R&D-driven specialty pharma focused on oncology and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announce that they are collaborating on the development of an investigational highly-selective RET inhibitor TAS0286/HM05, being evaluated in non-small cell lung cancer and other carcinomas. more info >> |
|
| Wednesday, March 28, 2018 |
|
|
Helsinn Healthcare S.A.: Winners of the inaugural Lyfebulb-Helsinn Innovation Summit & Awards in Oncology announced |
| Lyfebulb, a patient empowerment platform that connects patients, industry and investors to support user-driven innovation in chronic diseases, and Helsinn, with activities focused on early-stage investments in areas of high unmet patient need, today announced that Lorenzo Pradella of GreenBone Ortho, srl and Gitte Pedersen of Genomic Expression, Inc. have been chosen as winners of the first ever Lyfebulb-Helsinn Innovation Awards in Oncology. more info >> |
|
| Friday, March 2, 2018 |
|
|
Helsinn Healthcare S.A.: Eleven finalists have been chosen for the first ever Lyfebulb-Helsinn Innovation Summit & Award in Oncology |
| Lyfebulb, a patient empowerment platform that connects patients, industry and investors to support user-driven innovation in chronic diseases, and Helsinn, with activities focused on early-stage investments in areas of high unmet patient need, today announce the names of the eleven companies launched by patient entrepreneurs who are chosen as finalists for the Lyfebulb-Helsinn Innovation Summit & Award in Oncology. more info >> |
|
| Tuesday, October 17, 2017 |
|
|
Helsinn Pharmaceuticals (Beijing) Co. Ltd. Opens Office in Shanghai, China |
| Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces the approval of Helsinn Pharmaceuticals (Beijing) Co. Ltd., Shanghai branch, on August 7, 2017 by the Shanghai Administration for Industry and Commerce with a 30-year term. The full address and contact details of the Shanghai branch are found at the end of this announcement. more info >> |
|
| Friday, September 9, 2016 |
|
|
Helsinn and PatientsLikeMe Announce Results of NSCLC Patient Survey on Weight Loss |
| Helsinn Therapeutics (U.S.) Inc., the pharmaceutical group focused on building quality cancer care, and patient network PatientsLikeMe have unveiled findings from an online survey that captured experiences and insights about unintended weight loss and its burden among 95 patients living with non-small cell lung cancer. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
FWD Group survey reveals over 70 per cent of Asia's middle-class feel anxiety about financial wellbeing, preventing longer-term planning
Feb 4, 2026 13:30 JST
|
|
|
Formerra and Evonik Expand Distribution Partnership for Healthcare Grades
Feb 4, 2026 12:28 HKT/SGT
|
|
|
東方大鵬今日始：解碼「功能飲料第一股」東鵬飲料的長期價值底色
Feb 4, 2026 10:04 HKT/SGT
|
|
|
东方大鹏今日始：解码"功能饮料第一股"东鹏饮料的长期价值底色
Feb 4, 2026 10:04 HKT/SGT
|
|
|
Casa Minerals Inc. Announces Closing of First Tranche of Private Placement
Feb 4, 2026 07:59 HKT/SGT
|
|
|
先導智能赴港招股：新能源裝備龍頭 開啟全球增長新篇章
Feb 3, 2026 19:20 HKT/SGT
|
|
|
先导智能赴港招股：新能源装备龙头 开启全球增长新篇章
Feb 3, 2026 19:20 HKT/SGT
|
|
|
卡奧斯遞表港交所：工業數智化龍頭 為製造業培育新質生產力注入強勁動能
Feb 3, 2026 19:20 HKT/SGT
|
|
|
DENSO Announces Third Quarter Financial Results
Feb 3, 2026 19:36 JST
|
|
|
FWD Group survey reveals over 70 per cent of Asia's middle-class feel anxiety about financial wellbeing, preventing longer-term planning
Feb 3, 2026 15:13: JST
|
|
|
富士通、パブリックコメント業務に大規模言語モデル「Takane」を活用し、中央省庁で業務効率化の実証実験を実施
Feb 3, 2026 14:30: JST
|
|
|
富衛集團調查顯示逾七成亞洲中產對財務健康感到焦慮 阻礙長遠規劃
Feb 3, 2026 14:13 HKT/SGT
|
|
|
卡奧斯衝擊港股「AI+工業互聯網」第一股 數智生態賦能新型工業化
Feb 3, 2026 13:14 HKT/SGT
|
|
|
港股「釣魚第一股」樂欣戶外（2720.HK）啟動招股 將於2月10日正式上市
Feb 3, 2026 10:58 HKT/SGT
|
|
|
Fujitsu's Takane LLM successfully piloted in central government agency to streamline public comment operations
Feb 3, 2026 11:14 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
